Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 5:01 Acquisition Corp.FVAM · Entity 144989 | Director | October 16, 2020 | October 20, 2020 |
| Q32 Bio Inc.FIXX · Entity 5594 | Director | June 14, 2023 | June 15, 2023 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director | May 22, 2025 | May 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
5:01 Acquisition Corp.
Report date October 16, 2020 · Filed October 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2020-10-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-16 · Other · Acquired 30,000 · Balance 30,000 F1: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. F2: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors.
F2: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person.
Q32 Bio Inc.
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2033-06-14 | Direct | 23,000 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 23,000 · Balance 23,000 F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.
Vor Biopharma Inc.
Report date May 22, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2035-05-21 | Direct | 30,000 |
Reported balance
After 2025-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-22 · Grant · Acquired 30,000 · Balance 30,000 F1: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Audentes Therapeutics, Inc.
Report date January 15, 2020 · Filed January 15, 2020
Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 1
1 source rowRow 1 · 2020-01-15 · Other · Disposed 261,458 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest. F3: Includes 47,776 shares of Company common stock issuable upon the settlement of restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectBy Matthew R. Patterson Revocable Trust | 0 |
Reported balance
After 2020-01-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-01-15 · Other · Disposed 171,814 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F4: The reporting person is the trustee of the Matthew R. Patterson Revocable Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2025-12-18 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-15 · Disposition to issuer · Disposed 143,569 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.26 · Expires 2027-01-25 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-15 · Disposition to issuer · Disposed 188,334 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.39 · Expires 2027-11-16 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-15 · Disposition to issuer · Disposed 225,000 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-15 · Disposition to issuer · Disposed 177,450 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest.
F3: Includes 47,776 shares of Company common stock issuable upon the settlement of restricted stock units.
F4: The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 5,448 | $0.78 | $4,249.44 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · nonDerivative · entry 5 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 5,330 | $38.04 | $202,731.88 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · nonDerivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.88 and the highest price at which shares were sold was $38.21. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 5,330 | $0.78 | $4,157.40 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · nonDerivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 2,144 | $39.14 | $83,905.44 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $39.00 and the highest price at which shares were sold was $39.52. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4 and 5 to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 2,144 | $0.78 | $1,672.32 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 24, 2018 Filed Sep 24, 2018 18:12 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-052076 · doc4.xml · derivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,702 Underlying: Common Stock · 15,000 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| September 24, 2018 Filed Sep 24, 2018 18:12 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 15,000 | $0.78 | $11,700.00 |
DisclosureSEC source: 0001209191-18-052076 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 19:01 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 12,952 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-18-051837 · doc4.xml · derivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,345 Underlying: Common Stock · 12,952 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares will vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 19:01 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 12,952 | $40.00 | $518,080.00 |
DisclosureSEC source: 0001209191-18-051837 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 19:01 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 12,952 | $2.19 | $28,364.88 |
DisclosureSEC source: 0001209191-18-051837 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 23,147 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · derivative · entry 13 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,702 Underlying: Common Stock · 23,147 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 23,147 | $40.04 | $926,852.17 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · nonDerivative · entry 8 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $40.00 and the highest price at which shares were sold was $40.17. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 23,147 | $0.78 | $18,054.66 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · nonDerivative · entry 7 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 26,901 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · derivative · entry 12 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,849 Underlying: Common Stock · 26,901 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 26,901 | $40.05 | $1,077,460.37 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · nonDerivative · entry 6 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $40.00 and the highest price at which shares were sold was $40.55. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 26,901 | $0.78 | $20,982.78 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · nonDerivative · entry 5 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 1,401 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · derivative · entry 11 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,750 Underlying: Common Stock · 1,401 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 19,599 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · derivative · entry 10 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,151 Underlying: Common Stock · 19,599 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 1,401 | $38.78 | $54,329.80 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · nonDerivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $38.72 and the highest price at which shares were sold was $38.99. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 1,401 | $0.78 | $1,092.78 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · nonDerivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 19,599 | $38.33 | $751,194.39 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.71 and the highest price at which shares were sold was $38.71. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4 and 5 to this Form 4. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 18:34 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 19,599 | $0.78 | $15,287.22 |
DisclosureSEC source: 0001209191-18-041768 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 21, 2018 Filed May 23, 2018 18:13 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 20,300 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-032716 · doc4.xml · derivative · entry 6 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,750 Underlying: Common Stock · 20,300 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| May 21, 2018 Filed May 23, 2018 18:13 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 6,700 | $38.30 | $256,610.00 |
DisclosureSEC source: 0001209191-18-032716 · doc4.xml · nonDerivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $38.23 and the highest price at which shares were sold was $38.44. Read SEC document |
| May 21, 2018 Filed May 23, 2018 18:13 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 6,700 | $0.78 | $5,226.00 |
DisclosureSEC source: 0001209191-18-032716 · doc4.xml · nonDerivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 21, 2018 Filed May 23, 2018 18:13 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 13,600 | $38.08 | $517,888.00 |
DisclosureSEC source: 0001209191-18-032716 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.22 and the highest price at which shares were sold was $38.21. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| May 21, 2018 Filed May 23, 2018 18:13 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 13,600 | $0.78 | $10,608.00 |
DisclosureSEC source: 0001209191-18-032716 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 21:01 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 700 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-023956 · doc4.xml · derivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,050 Underlying: Common Stock · 700 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 21:01 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 700 | $30.01 | $21,009.03 |
DisclosureSEC source: 0001209191-18-023956 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $30.00 and the highest price at which shares were sold was $30.03. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 21:01 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 700 | $0.78 | $546.00 |
DisclosureSEC source: 0001209191-18-023956 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 19:27 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee stock option · Derivative | 8,360 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008923 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,360 Underlying: Common Stock · 8,360 shares Expires 2028-03-27 F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 17:07 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $27.39 | $0.00 |
DisclosureSEC source: 0001209191-17-061544 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-11-16 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:25 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-17-056048 · doc4.xml · derivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,750 Underlying: Common Stock · 10,000 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:25 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 15,000 | $27.92 | $418,852.50 |
DisclosureSEC source: 0001209191-17-056048 · doc4.xml · nonDerivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Matthew R. Patterson Revocable Trust Disclosed balance after: 171,814 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $27.58 and the highest price at which shares were sold was $28.36. F4 · ownership.nature: The reporting person is the trustee of the Matthew R. Patterson Revocable Trust. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:25 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 10,000 | $27.92 | $279,217.00 |
DisclosureSEC source: 0001209191-17-056048 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $27.60 and the highest price at which shares were sold was $28.35. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:25 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 10,000 | $0.78 | $7,800.00 |
DisclosureSEC source: 0001209191-17-056048 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 18:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 8,458 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-17-053351 · doc4.xml · derivative · entry 7 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,750 Underlying: Common Stock · 8,458 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 18:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 8,458 | $25.07 | $212,009.92 |
DisclosureSEC source: 0001209191-17-053351 · doc4.xml · nonDerivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $25.00 and the highest price at which shares were sold was $25.45. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 18:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 8,458 | $0.78 | $6,597.24 |
DisclosureSEC source: 0001209191-17-053351 · doc4.xml · nonDerivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 18:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 1,542 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-17-053351 · doc4.xml · derivative · entry 6 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,208 Underlying: Common Stock · 1,542 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 18:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 1,542 | $25.00 | $38,550.93 |
DisclosureSEC source: 0001209191-17-053351 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $25.00 and the highest price at which shares were sold was $25.01. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 18:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 1,542 | $0.78 | $1,202.76 |
DisclosureSEC source: 0001209191-17-053351 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 20:01 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 12,150 | $20.00 | $243,052.25 |
DisclosureSEC source: 0001209191-17-045270 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Matthew R. Patterson Revocable Trust Disclosed balance after: 186,814 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the average weighted sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.06. F3 · ownership.nature: The reporting person is the trustee of the Matthew R. Patterson Revocable Trust. Read SEC document |
| July 12, 2017 Filed Jul 14, 2017 20:01 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 2,850 | $20.00 | $57,007.13 |
DisclosureSEC source: 0001209191-17-045270 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Matthew R. Patterson Revocable Trust Disclosed balance after: 198,964 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the average weighted sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.03. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · ownership.nature: The reporting person is the trustee of the Matthew R. Patterson Revocable Trust. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:09 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0001209191-17-005998 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.